Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experience

Epidermal growth factor receptor (EGFR) gene mutations identify a molecularly defined subset of non-small cell lung cancer (NSCLC) patients who display an excellent sensitivity to EGFR tyrosine kinase inhibitors (TKIs). First-generation reversible EGFR TKIs, gefitinib and erlotinib have been proven...

Full description

Saved in:
Bibliographic Details
Published in:Ther Adv Respir Dis
Main Authors: Ricciuti, Biagio, Baglivo, Sara, De Giglio, Andrea, Chiari, Rita
Format: Artigo
Language:Inglês
Published: SAGE Publications 2018
Subjects:
Review
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6204616/
https://ncbi.nlm.nih.gov/pubmed/30355049
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466618808659
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items